Document Migration

WHITE PAPERS AND CASE STUDIES

• Comprehensive Pathway To Seamless Scale-Up Of mRNA DP Manufacturing

  An integrated approach to mRNA drug product manufacturing helps to accelerate drug development, mitigate risks, and ultimately deliver life-changing therapies to patients.

• Designing For Diversity

  Embracing diversity enhances our understanding of humanity, fostering empathy and a broader perspective on the world's cultures and behaviors.

• OEE And Product Inspection

  Explore the calculation of Overall Equipment Effectiveness (OEE) and the impact of product inspection equipment on OEE in the pharmaceutical industry.

• DECODE CRS: Accelerating Immunotherapy Access And De-risking CRS

  How does the DECODE CRS Coalition help trial sponsors standardize protocols and build a first-of-its-kind wearable dataset to lower development costs and safely de-risk outpatient care?

• 3D Scanning System Brings Digital Characters To Life

  Explore how advancements in visual effects, driven by high-speed 3D digital capture systems from Pixel Light Effects, are transforming the entertainment industry.

• Building A Legacy In Sterile Injectables Through Strong CMO Synergy

  Examine how a CMO can deliver significant value to drug developers by fostering successful outsourcing, streamlining the path to market, and supporting demands.

• The Growing Role Of RF N-Plexers In Next-Generation On RF Front-End Architectures

  Explore the growing role of RF N-plexers in addressing multiband operation, wider-band antennas, system integration, and scalable front-end architectures.

• Choosing The Right Platform: A Comparison For Regulated Industries

  Regulated industries depend on tightly controlled review workflows, yet common tools rarely meet those demands. Explore how purpose‑built solutions strengthen compliance and help streamline timelines.

• Where Innovation And Investment Reduce Drug Development Risk

  How strategic investments in development, manufacturing, and clinical supply are helping organizations reduce risk and accelerate drug development.

• Reducing Risk And Timelines In Cell Line Development

  Accelerate your biologic development by adopting faster, more reliable clone selection methods that reduce time and resources while improving the likelihood of identifying stable, high-producing cell lines.

• Manufacturing Of Cytotoxic And Non-Cytotoxic Drugs In A Multiproduct Facility

  The experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.

• Sustainability In Small Molecule API Manufacturing

  Redesigning chemical processes with green chemistry principles can cut emissions, reduce waste, and improve efficiency. See how smarter synthesis and digital tools enable sustainable API manufacturing.